Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

An update on cirrhotic cardiomyopathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Methotrexate for inflammatory bowel disease: time for reconsideration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucagon like peptide-2 and neoplasia; a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Advances in the treatment of portal hypertension in cirrhosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. The role and advances of immunomodulator therapy for inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Introduction: Cirrhosis with portal hypertension and related complications are associated with a high mortality. Excess of circulating vasodilators and cardiodepressive substances lead to a hyperdynamic circulation with changed myocardial structure and function. The entity cirrhotic cardiomyopathy seems to be involved in different aspects of hepatic decompensation, which focuses on new targets of treatment. Areas covered: This review deals with contemporary aspects of cirrhotic cardiomyopathy, and the literature search was undertaken by PubMed with ‘cirrhotic’ and ‘cardiomyopathies’ as MeSH Terms. Cirrhotic cardiomyopathy is defined as the presence of systolic and diastolic dysfunction and electrophysiological abnormalities. The diagnosis is based on contemporary Doppler/Echocardiography measurements or quantitative magnetic resonance imaging. Cirrhotic cardiomyopathy is independent of the etiology of the liver disease but related to severity and survival. Expert commentary: The outcome of invasive procedures and liver transplantation is influenced by the presence of cardiac dysfunction. Therefore, a cautious cardiac evaluation should be included in the patient evaluation prior to liver transplantation. Liver transplantation ameliorates most of the abnormalities seen in cirrhotic cardiomyopathy, but no specific treatment can yet be recommended.

OriginalsprogEngelsk
TidsskriftExpert review of gastroenterology & hepatology
Vol/bind13
Udgave nummer5
Sider (fra-til)497-505
Antal sider9
ISSN1747-4124
DOI
StatusUdgivet - maj 2019

ID: 56740179